1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Guerbet S.A.

Guerbet S.A.

GBT.PA
Guerbet S.A.undefined flagEuronext Paris
8.71
EUR
-0.10
- -
109.79MMarket Cap
Guerbet S.A.
GBT.PA
(Euronext Paris)

Recent

price

8.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
28.94
31.05
33.14
32.01
33.54
40.09
62.4
64.56
63.18
65.06
56.88
58.33
60.99
62.94
67.53
- -
Revenue per Share
0.48
1.18
1.67
1.68
2.14
3.21
2.33
3.69
3.72
2.97
1.45
2.59
-3.26
1.89
1.28
- -
Basic EPS, GAAP
-0.28
0.1
0.84
1.85
2.36
2.4
-0.89
0.76
2.62
0.28
4.82
5.31
-1.59
-2.1
1.92
- -
Free Cash Flow per Basic Share
0.56
0.45
0.45
0.5
0.5
0.5
0.64
0.86
0.85
0.85
0.7
0.7
0.85
0.5
0.5
- -
Dividend per Share
1.48
2.18
2.67
2.68
3.14
4.22
3.33
4.69
4.72
3.97
2.45
3.59
-2.26
2.89
2.28
- -
Book Value per Share
14.47
14.67
15.57
16.56
17.66
15.59
16.78
18.64
14.66
15.84
14.25
17.16
22.32
22.24
22.6
- -
Tangible Book Value per Share
12
12
12
12
12
12
12
13
13
13
13
13
13
13
13
- -
Basic Weighted Avg Shares
353
379
404
391
409
490
776
809
795
819
717
736
769
796
851
799
Sales/Revenue/Turnover
2.35
5.95
8.29
7.69
9.57
12.25
7.21
10.02
8.32
6.32
5.97
5.36
5.58
4.92
5.73
1.01
Operating Margin (%)
20
20
22
24
25
29
49
43
42
59
58
58
123
58
73
162
Depreciation Expense
6
14
20
20
26
39
29
46
47
37
18
33
-41
24
16
-108
Net Income, GAAP
- -
- -
- -
- -
- -
35.6
- -
- -
- -
27.1
18.02
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.67
3.81
5.05
5.25
6.38
8.01
3.73
5.72
5.89
4.56
2.55
4.43
-5.34
3
1.89
-13.56
Profit Margin (%)
102
84
88
88
90
243
296
295
157
299
268
259
270
352
335
359
Working Capital
- -
80
67
62
45
301
331
287
193
341
318
300
278
374
351
392
LT Debt
211
215
226
238
259
282
315
342
367
389
368
405
380
378
392
260
Total Equity
- -
- -
- -
- -
- -
7.74
- -
- -
- -
4.79
4.69
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
15.58
- -
- -
- -
9.38
5.48
- -
- -
- -
- -
- -
Return on Capital (%)
23.18
64.54
68.89
62.76
73.57
87.27
62.21
92.24
79.23
68.29
45.17
85.75
- -
- -
49.31
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.14%
-5.31%
-33.58%
Free Cash Flow
128.85%
-38.91%
83.6%
Net Income, GAAP
-114.78%
-222.25%
-773.53%
Sales/Revenue/Turnover
6.29%
2.29%
-6.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
796
2024
- -
- -
- -
- -
851
2025
- -
- -
- -
- -
799

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.89
2024
- -
- -
- -
- -
1.28
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.5
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
- -
Similar Companies
OMID Holdings, Inc. (OMID)
Tibet Weixinkang Medicine Co., Ltd. (603676.SS)
Glass House Brands Inc. (GLASF)
Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)
Endo International plc (ENDP)
Business
Guerbet S.A. Guerbet SA develops, manufactures and markets contrast agents, delivery systems, medical devices and related solutions for diagnostic and interventional medical imaging, including X-ray imaging products such as Xenetix, Optiray, Oxilan and Telebrix; MRI products such as Dotarem; and other contrast products for echography, nuclear medicine and fine chemicals, along with brands including Lipiodol, Endorem, Artirem and Lumirem. The company operates production sites in France, the United States, Ireland and Brazil, with Europe accounting for 37% of net sales; it targets healthcare providers in diagnostic imaging (MRI and CT) and interventional radiology segments worldwide. Founded in 1926 and headquartered at 15 rue des Vanesses, Zone Paris Nord II, Villepinte, France, Guerbet recently formed a strategic partnership with Nuclidium on May 22, 2024, to develop targeted copper-based radiopharmaceuticals, sold assets including the SeQure and DraKon microcatheters to Argon Medical in January 2025 to expand its oncology portfolio, reported revenue of €851 million in 2024 with return to growth in Q3 2025, and announced a change in general management while confirming full-year financial targets.